Joseph Schérer

Proteomic Exploration of L1CAM+-Extracellular Vesicles from Plasma of Manifest and Prodromal Parkinson’s Disease

Mary Xylaki, A Chopra, Yevheniia Kyriachenko, Joseph Schérer et autres

L1 cell adhesion molecule (L1CAM)-positive extracellular vesicles (EVs) are being explored as a potential source of biomarkers for Parkinson’s disease (PD) in peripheral blood. However, their utility remains controversial. In this study, we sought to investigate the proteome composition of L1CAM+-EVs isolated …

de (code pays fourni par la source)

Design Instrumentation in an Immersive Virtual Environment

Dave Lee, Brantley Crile, Joseph Schérer

This research examines the integration of Immersive Virtual Environments (IVE) in an architectural design workflow. Of particular interest to this research is the use of relatively inexpensive and commercially available Head Mounted Displays and controllers, paired with existing software, to test a …

us (code pays fourni par la source)

Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir

Kristi L. Berger, Christoph Sarrazin, David R. Nelson, Joseph Schérer et autres

BACKGROUND & AIM: The resistance profile of anti-hepatitis C virus (HCV) agents used in combination is important to guide optimal treatment regimens. We evaluated baseline and treatment-emergent NS3/4A and NS5B amino-acid variants among HCV genotype (GT)-1a and -1b-infected patients treated with faldaprevir …

ca, us, de (code pays fourni par la source)

Safety and efficacy of faldaprevir in combination with pegylated interferon α‐2b and ribavirin in Japanese patients with genotype‐1 chronic hepatitis C virus infection

Shuhei Nishiguchi, Yasuhisa Urano, Keiko Suzaki, Atsushi Taniguchi et autres

AIM: We evaluated the safety and efficacy of the hepatitis C virus (HCV) NS3/4A A protease inhibitor faldaprevir plus pegylated interferon α-2b and ribavirin (PegIFNα-2b/RBV) in Japanese patients with HCV genotype-1 infection. METHODS: Treatment-naïve patients were randomized (1:1) to faldaprevir 120 mg …

jp, ph, us (code pays fourni par la source)

Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials

Donald M. Jensen, Tarik Asselah, Douglas T. Dieterich, Graham R. Foster et autres

INTRODUCTION & AIM: Faldaprevir is a potent once-daily (q.d.) hepatitis C virus (HCV) NS3/4A protease inhibitor. The STARTVerso1 and STARTVerso2 phase 3 studies evaluated faldaprevir plus peginterferon alfa-2a/ribavirin (PegIFN/RBV) in treatment-naïve patients with chronic HCV genotype-1 infection. MATERIAL AND METHODS: Patients were …

us, fr, gb, de, ca, be, jp, tw, kr, at (code pays fourni par la source)

Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial

David A. Cooper, Damien V. Cordery, Roberto Zajdenverg, Kiat Ruxrungtham et autres

Ritonavir-boosted tipranavir (TPV/r) was evaluated as initial therapy in treatment-naïve HIV-1-infected patients because of its potency, unique resistance profile, and high genetic barrier. Trial 1182.33, an open-label, randomized trial, compared two TPV/r dose combinations versus ritonavir-boosted lopinavir (LPV/r). Eligible adults, who had …

au, br, th, de, us (code pays fourni par la source)

Baseline Polymorphisms and Emergence of Drug Resistance in the NS3/4A Protease of Hepatitis C Virus Genotype 1 following Treatment with Faldaprevir and Pegylated Interferon Alpha 2a/Ribavirin in Phase 2 and Phase 3 Studies

Kristi L. Berger, Joseph Schérer, Mithun Ranga, Nanshi Sha et autres

Analysis of data pooled from multiple phase 2 (SILEN-C1 to 3) and phase 3 studies (STARTVerso1 to 4) of the hepatitis C virus (HCV) nonstructural protein 3/4A (NS3/4A) protease inhibitor faldaprevir plus pegylated interferon alpha/ribavirin (PR) provides a comprehensive evaluation of baseline …

us, ca (code pays fourni par la source)

STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection

Peter Ferenci, Tarik Asselah, Graham R. Foster, Stefan Zeuzem et autres

BACKGROUND & AIMS: The efficacy and tolerability of faldaprevir, a potent hepatitis C virus (HCV) NS3/4A protease inhibitor, plus peginterferon (PegIFN) and ribavirin (RBV) was assessed in a double-blind, placebo-controlled phase 3 study of treatment-naïve patients with HCV genotype-1 infection. METHODS: Patients …

at, fr, gb, de, be, ru, pt, es, ch, jp, us (code pays fourni par la source)

Su1054 Ns3 Q80k Did Not Impact Efficacy or Treatment-Emergent Resistance Patterns in HCV Genotype-1-Infected Patients Receiving Faldaprevir Plus Pegylated Interferon/Ribavirin in Three Phase III Trials

Kristi L. Berger, Christoph Sarrazin, Péter Ferenci, Donald M. Jensen et autres

Su1058 Early Stopping Rules for Faldaprevir Plus Pegylated Interferon α-2A and Ribavirin in Treatment-Naïve Patients: Exploratory Study of Pooled Data From Phase III Trials

Péter Ferenci, Douglas T. Dieterich, Stefan Zeuzem, Parvez Mantry et autres

Su1020 Faldaprevir Efficacy in HCV Genotype-1-Infected Patients in Four Phase III Trials: Analysis by Ns3 Baseline Polymorphisms, Genotype-1 Subtype and Genotype-1A Clades

Kristi L. Berger, Christoph Sarrazin, Ira M. Jacobson, Donald M. Jensen et autres

Su1056 Effect of HCV Genotype-1 Subtype on Response to Faldaprevir Plus Pegylated Interferon α-2A and Ribavirin in Treatment-Naïve Patients: Pooled Data From Phase III Trials

Ira M. Jacobson, Donald M. Jensen, Douglas T. Dieterich, Christoph Sarrazin et autres